SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently trending as it pushes to new all-time highs, signaling a potential breakout phase that has the community divided between bullish momentum chasers and those skeptical of its massive market valuation. Investors are actively debating whether this movement marks the start of a sustained expansion or a temporary peak ahead of upcoming earnings, with many monitoring the stock as a bellwether for the broader semiconductor sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a massive sell-off after Marvell cancelled all purchase orders citing an NDA breach, fueling intense community debate over management's professional conduct and the future viability of their technology. Investors are actively questioning the company's credibility and long-term path forward, with discussions centered on potential legal fallout, executive accountability, and whether this represents a total loss of trust or a speculative buying opportunity.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail interest driven by its status as a high-volatility, low-float stock capable of rapid price movements. Community sentiment remains highly polarized, with active discussions focused on the potential for short squeezes, recent corporate governance updates, and skepticism surrounding the stock's long-term sustainability.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors digest the strategic consolidation of its Tanbreez rare earth asset and the potential impact of a significant share-canceling acquisition of European Lithium. The community is actively debating the stock's role in securing Western defense supply chains and closely monitoring institutional activity and borrowing costs as indicators of a potential short squeeze.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing a surge driven by significant institutional accumulation, aggressive insider buying, and positive clinical momentum surrounding its paridiprubart trial results. Community members are actively speculating about potential buyout scenarios and near-term regulatory catalysts, while debating the impact of the stock's low effective float on its recent volatile price action.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as investors digest a solid quarterly earnings beat, with strong sales growth driven by aggressive value strategies and loyalty program engagement. The stock has seen heightened activity and volatility as traders weigh the chain's ability to maintain resilient performance amid persistent inflation and shifting consumer dining habits.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a major focus for traders as the market digests recent Phase 3 trial results for its gene-editing candidate, with community sentiment split between those viewing the data as a revolutionary clinical breakthrough and those concerned about commercialization risks. While some investors are betting on a potential short squeeze given the stock's high short interest, others are actively debating the impact of the company's ATM offering and clinical trial safety profiles.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as traders analyze a potential $100 billion windfall from its early SpaceX investment alongside news of a strategic collaboration with Marvell to develop custom AI inference chips. The community is heavily focused on these structural growth catalysts as they position for upcoming earnings, with many viewing the company's expanding AI infrastructure as a key long-term differentiator.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened investor attention as community members debate its potential for a turnaround, driven by optimism regarding upcoming earnings, a massive stock buyback program, and rumors of a strategic smartphone processor partnership with OpenAI. While many bulls view the stock as undervalued and primed for a rotation, others remain skeptical, pointing to persistent overhead supply and disappointment over its recent price action following the announcement of AI-related collaborations.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently attracting investor attention following a positive Phase 3 clinical trial readout for its denifanstat treatment in acne patients, which bolsters its pipeline and clinical derisking narrative. The community is actively discussing the stock's long-term potential in the MASH and acne markets, while closely monitoring institutional accumulation and potential interest from larger pharmaceutical players for a future partnership or acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has received an average rating of "Hold" from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have iss...

SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay

Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.

<ul class="summary-bullets"><li>The firm said MGNX is uniquely positioned in the emerging Antibody-Drug Conjugate therapy space.</li><li>B. Riley said Gilead’s $5 billion acquisition of Tubulus earlier this week prompted it to develop its own valuation models for ADC firms.</li><li>On Wednesday, MGNX said the U.S. FDA has lifted the partial clinical hold on its Phase 2 trial of a drug to treat cancer.</li></ul>Shares of MacroGenics (MGNX) surged around 10% on Friday, with the stock hitting its highest levels since November 2024. This comes after a bullish analyst call highlighted significant upside potential, with the firm projecting gains of up to 140% from current levels.On Friday, B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.<h2 class="st-heading-2">B. Riley Upgrades Stock After Gilead Tubulus Deal</h2>The brokerage said that after Gilead Sciences’ (GILD) $5 billion deal to acquire Tubulus earlier this week, it developed its own valuation model for next-generation Antibody-Drug Conjugate (ADC) companies and believes MGNX is uniquely positioned in the emerging “ADAM9 TOPO1i ADC space.”ADC is a cancer treatment that combines targeted therapy and chemotherapy.On Tuesday, Gilead Sciences (GILD) <a href="https://stocktwits.com/news-articles/markets/equity/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc">entered</a> into a definitive agreement to acquire Tubulis GmbH, a German clinical-stage biotechnology company. Gilead will pay $3.15 billion upfront, and up to $1.85 billion in additional milestone payments.The deal strengthens Gilead’s ADC pipeline by adding Tubulis’ assets, including TUB-040, a drug in development for ovarian and non-small cell lung cancers.<h2 class="st-heading-2">FDA Lifts Partial Clinical Hold On Ovarian Cancer Trial</h2>On Wednesday, MGNX said the U.S. FDA had lifted the partial clinical hold on its Phase 2 LINNET study of Lorigerlimab, a cancer drug. The trial is testing the drug in patients with certain advanced ovarian and gynecologic cancers who have already received prior treatments.So far, 41 patients have been treated in the study, with over 300 patients dosed across earlier trials.Existing patients were allowed to continue treatment during the hold, and the study will now resume enrolling new patients under an updated protocol with added safety measures.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MGNX">MGNX</a> on Stocktwits flipped to ‘bullish’ from ‘bearish’, amid high message volumes.One user said the stock’s valuation was “too low.”<stembedurl>https://stocktwits.com/perchedcats/message/649223850</stembedurl>Year-to-date, the stock has surged around 133%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside

B. Riley upgraded MacroGenics to ’Buy’ from ‘Neutral’ with a $9 price target, according to The Fly.

Equity

MacroGenics (NASDAQ:MGNX) Raised to "Buy" at B. Riley Financial

B. Riley Financial raised shares of MacroGenics from a "neutral" rating to a "buy" rating and set a $9.00 target price for the company in a research note on Friday...

JPMorgan Chase & Co. Increases Stake in MacroGenics, Inc. $MGNX

JPMorgan Chase & Co. increased its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 64.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional...

MacroGenics (NASDAQ:MGNX) Stock Crosses Above Fifty Day Moving Average   - What's Next?

MacroGenics (NASDAQ:MGNX) Stock Price Passes Above 50-Day Moving Average - Time to Sell...

MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving Average   - Time to Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Above 50-Day Moving Average - Time to Sell...

MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.</li><li>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.&nbsp;</li><li>The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.</li></ul> Barclays on Tuesday raised the firm's price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.<h2 class="st-heading-2">Pipeline Updates</h2>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026, Risser said.Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MGNX">MGNX stock</a> has gained more than 50% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/viking-ceo-sees-its-obesity-drug-beating-novo-wegovy-in-weight-loss/cZdozzNRI7l">Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 

Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock

Barclays increased their price target on MacroGenics from $3.00 to $4.00 and gave the company an "overweight" rating in a research report on Tuesday...

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Current Price	$3.06
Prev Close	$3.19
Open	$3.23
Dividend Yield	0.00%
50-Day Moving Average	$2.75
Beta	1.43
Avg. Volume	1.61M
PE Ratio	-2.70

52-Week High	$3.88
52-Week Low	$1.19
Market Capitalization	$202.76M
EPS (Annual)	-$1.18
Price to Book	3.63
Revenue Per Employee	$510,238.91

MGNX
Macrogenics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGNX News

MGNXMacrogenics Inc